DYAI 8-K SEC Filing Analysis

Latest settled — T+5d

DYAI ▼ -1.41% at T+5d

NEUTRAL call ✗ call lost -1.41% · α vs SPY -1.36% · entry $0.7100 → $0.7000

Next anchor: T+20d in 7d

Last close $0.8500 (close Jun 17) · +19.72% from $0.7100 entry

Entry anchored
May 28, 07:50 AM ET
via Databento tick

T+1d

+14.08%

call +14.08% · α +13.84%

$0.8100

settled 21d ago

T+5d

-1.41%

call -1.41% · α -1.36%

$0.7000

settled 15d ago

T+20d

—

call — · α —

—

in 7d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Dyadic (DYAI) announced a research collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, using Dyadic's C1 microbial protein production platform. The collaboration builds on prior funded work with the Gates Foundation and CEPI, aims to leverage non-dilutive grants, and has no disclosed upfront payment or near-term revenue impact.

Actionable Insight

The Scripps collaboration is a positive platform validation event but lacks financial terms or near-term revenue catalysts. DYAI has historically seen significant positive drift on neutral news (T+20 avg +11.31% on last 3 reports). Monitor for follow-on grant awards or partnership announcements that could provide funded development milestones.

Key Facts

Dyadic and Scripps Research collaborating on hantavirus (Andes virus) antibody and vaccine development
Collaboration leverages Dyadic's C1 microbial platform for rapid, scalable biologic production
No disclosed upfront payment, milestone payments, or funding commitment
Parties plan to seek external non-dilutive funding (grants, sponsored research)
Prior Andes virus mAb work showed neutralization comparable to ExpiCHO-produced material (preclinical)
Dyadic is involved in other funded collaborations with Gates Foundation, CEPI, and FBS
Commercial focus remains on non-pharmaceutical protein products and industrial biomanufacturing

Financial Impact

No disclosed financial terms, upfront payments, or funding commitments. Collaboration structured as grant-funded research with no dilution.

Risk Factors

No funded commitment — collaboration is exploratory (evaluate potential) and depends on securing external grants
Preclinical stage — hantavirus antibody/vaccine candidates are years from potential commercialization
DYAI's primary commercial focus is non-pharmaceutical proteins; biopharma collaborations are validation but not core revenue drivers
History of net losses and uncertain commercialization timeline for C1 platform

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-025554
Exhibit: ex99-1.htm	0001493152-26-025554
Document: 0001493152-26-025554-index-headers.html	0001493152-26-025554
Document: 0001493152-26-025554-index.html	0001493152-26-025554
Document: 0001493152-26-025554.txt	0001493152-26-025554

5 reports for DYAI

T+1T+5T+20T+60

Filters

Reports for DYAI — sortable, filterable
	Type				Now
Jun 18, 2026 today	DEFA14A BEARISH ★ 8/10	$0.8416 awaiting T+5	awaiting T+5	—	$0.8500 (−1.00%)
May 28, 2026 21d ago	8-K NEUTRAL ★ 4/10	$0.7100 $0.7000	▼ −1.41%	▼ −1.36%	$0.8500 (+19.72%)
Mar 25, 2026 12w ago	Press Release MIXED ★ 5/10	$0.7000 $0.8900	▲ +27.14%	▲ +25.51%	$0.8500 (+21.43%)
Mar 16, 2026 13w ago	Press Release MIXED ★ 5/10	$0.8100 $0.8600	▲ +6.17%	▲ +8.21%	$0.8500 (+4.94%)
Mar 4, 2026 15w ago	Press Release NEUTRAL ★ 4/10	$0.8200 $0.8000	▼ −2.44%	▼ −1.11%	$0.8500 (+3.66%)

US Market Status

Market Closed — Juneteenth — Opens Mon (77h 18m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access